Complement components of the innate immune system in health and disease in the CNS

Immunopharmacology

Volumn 49, Issue 1-2, 2000, Pages 171-186

  Gasque, P ^a   Dean, Y D ^a   McGreal, E P ^a   Vanbeek, J ^b   Morgan, B P ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UMR 6551 CNRS   (France)

Author keywords

Anaphylatoxin; Apoptosis; Brain; Complement; Inflammation; Opsonin; Phagocytosis

Indexed keywords

ANAPHYLATOXIN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; OPSONIN;

COMPLEMENT ACTIVATION; CONFERENCE PAPER; ENCEPHALITIS; HUMAN; HUNTINGTON CHOREA; IMMUNE SYSTEM; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW;

EID: 0033921540     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(00)80302-1     Document Type: Conference Paper

References (125)

1. Afagh A, Cummings B.J., et al. Localization and cell association of C1q in Alzheimer's disease brain. Experimental Neurology. 138:1996;22-32.
2. Agoropoulo C., Wing M.G., et al. CD59 expression and complement susceptibility of human neuronal cell line (NTera2). NeuroReport. 7:1996;997-1004.
3. Ahearn J.M., Rosengard A.M. Complement receptors. Volanakis J.E., Fank M.M. The Human Complement System in Health and Disease. 1998;167-202 Marcel Dekker, New York.
4. Akiyama H., Kawamata T, et al. Immunohistochemical localization of Vitronectin, its receptor and beta-3 integrin in Alzheimer brain-tissue. Journal of Neuroimmunology. 32:1991a;19-28.
5. Akiyama H., Yamada T., et al. Association of amyloid-P component with complement proteins in neurologically diseased brain-tissue. Brain Research. 548:1991b;349-352.
6. Avery V.M., Adrian D.L., et al. Detection of mosaic protein messenger-RNA in human astrocytes. Immunology and Cell Biology. 71:1993;215-219.
7. Badea T., Niculescu F., et al. Molecular cloning of RGC-32, a novel gene induced by complement activation in oligodendrocyte. Molecular Immunology. 35:1998;276.
8. Barnum S.R. Complement biosynthesis in the central-nervous-system. Critical Reviews in Oral Biology and Medicine. 6:1995;132-146.
9. Barnum S.R., Ishii Y., et al. Production and interferon-gamma-mediated regulation of complement component C2 and factor-B and factor-D by the astroglioma cell-line U 105-MG. Biochemical Journal. 287:1992a;595-601.
10. Barnum S.R., Jones J. Differential regulation of C3 gene-expression by gamma-interferon and interleukin-1 in the astroglioma cell-line D54-MG. Faseb Journal. 6:1992;A1452.
11. Barnum S.R., Jones J., et al. Gamma-interferon (IFN-gamma)-mediated regulation of C3 by D54-MG astroglioma cells and primary rat astrocytes. Faseb Journal. 5:1991;A1781.
12. Barnum S.R., Jones J.L., et al. Differential regulation of C3 gene-expression in human astroglioma cells by interferon-gamma and interleukin-1-beta. Neuroscience Letters. 197:1995;121-124.
13. Barnum S.R., Jones J.L., et al. Interferon-gamma regulation of C3-gene expression in human astroglioma cells. Journal of Neuroimmunology. 38:1992b;275-282.
14. Barnum S.R., Jones J.L., et al. Interleukin-1 and tumor necrosis factor-mediated regulation of C3 gene-expression in human astroglioma cells. Glia. 7:1993;225-236.
15. Bradt B.M., Kolb W.P., et al. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. Journal of Experimental Medicine. 188:1998;431-438.
16. Czermak B.J., Lentsch A.B., et al. Synergistic enhancement of chemokine generation and lung injury by C5a or the membrane attack complex of complement. American Journal of Pathology. 154:1999;1513-1524.
17. DandoyDron F., Guillo F., et al. Gene expression in scrapie-cloning a new scrapie-responsive gene and the identification of increased levels of seven other mRNA transcripts. Journal of Biological Chemistry. 273:1998;7691-7697.
18. Davoust N., Jones J., et al. Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells. Glia. 26:1999a;201-211.
19. Davoust N., Nataf S., et al. Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis. Journal of Immunology. 163:1999b;6551-6556.
20. Dietzschold B., Schwaeble W., et al. Expression of C1q, a subcomponent of the rat complement-system, is dramatically enhanced in brains of rats with either borna-disease or experimental allergic encephalomyelitis. Journal of the Neurological Sciences. 130:1995;11-16.
21. Eikelenboom P., Hack C.E., et al. Complement activation in amyloid plaques in Alzheimers dementia. Virchows Archiv B - Cell Pathology Including Molecular Pathology. 56:1989;259-262.
22. Eikelenboom P., Stam F.C. Immunoglobulins and complement factors in senile plaques-an immunoperoxidase study. Acta Neuropathologica. 57:1982;239-242.
23. Eikelenboom P., Stam F.C. An immunohistochemical study on cerebral vascular and senile plaque amyloid in Alzheimers dementia. Virchows Archiv B - Cell Pathology Including Molecular Pathology. 47:1984;17-25.
24. Ember J.A., Jagels M.A., et al. Characterization of complement anaphylatoxins and their biological responses. Volanakis J.E., Frank M.M. The Human Complement System in Health and Disease. 1998;241-284 Marcel Dekker, New York.
25. Fabry Z., Raine C.S., et al. Nervous-tissue as an immune compartment - the dialect of the immune-response in the Cns. Immunology Today. 15:1994;218-224.
26. Farkas I., Baranyi L., et al. Complement C5a anaphylatoxin fragment causes apoptosis in TGW neuroblastoma cells. Neuroscience. 86:1998;903-911.
27. Fearon D.T., Locksley R.M. The instructive role of innate immunity in the acquired immune response. Science. 272:1996;50-54.
28. Fischer B., Schmoll H., et al. Complement C1q and C3 messenger-RNA expression in the frontal-cortex of Alzheimers patients. Journal of Molecular Medicine-Jmm. 73:1995;465-471.
29. Frank M.M., Fries L.F. The role of complement in inflammation and phagocytosis. Immunology Today. 12:1991;322-326.
30. Gasque P., Chan P., et al. Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. Journal of Immunology. 155:1995a;4882-4889.
31. Gasque P., Chan P., et al. Identification and characterization of complement C3 receptors on human astrocytes. Journal of Immunology. 156:1996a;2247-2255.
32. Gasque P., Chan P., et al. Characterisation of expression of complement receptor type 4 (CR4) by human glia. Molecular Immunology. 35:1998a;198.
33. Gasque P., Fontaine M., et al. Complement expression in human brain-biosynthesis of terminal pathway components and regulators in human glial-cells and cell-lines. Journal of Immunology. 154:1995b;4726-4733.
34. Gasque P., Ischenko A., et al. Expression of the complement classical pathway by human glioma in culture - a model for complement expression by nerve-cells. Journal of Biological Chemistry. 268:1993;25068-25074.
35. Gasque P., Julen N., et al. Expression of complement components of the alternative pathway by glioma cell-lines. Journal of Immunology. 149:1992;1381-1387.
36. Gasque P., Morgan B.P. Complement regulatory protein expression by a human oligodendrocyte cell line: cytokine regulation and comparison with astrocytes. Immunology. 89:1996;338-347.
37. Gasque P., Singhrao S.K., et al. Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. American Journal of Pathology. 150:1997;31-41.
38. Gasque P., Singhrao S.K., et al. C3aR is a marker of inflammation and gliosis in human neurodegenerative disorders. Molecular Immunology. 35:1998b;197.
39. Gasque P., Singhrao S.K., et al. Expression of C3aR in man and mouse: predominance in adrenal gland, skin and lung. Molecular Immunology. 35:1998c;196.
40. Gasque P., Singhrao S.K., et al. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. Journal of Immunology. 160:1998d;3543-3554.
41. Gasque P., Tenner A., et al. Expression of the C1q/MBL/SPA receptor involved in phagocytosis and innate immune defense on human glia. Molecular Immunology. 35:1998e;195.
42. Gasque P., Thomas A., et al. Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins. Journal of Neuroimmunology. 66:1996b;29-40.
43. Gewurz H., Ying S.C., et al. Nonimmune activation of the classical complement pathway. Behring Institute Mitteilungen. 93:1993;138-147.
44. Gordon D.L., Avery V.M., et al. Detection of complement protein messenger-Rna in human astrocytes by the polymerase chain-reaction. Journal of Neuroscience Methods. 45:1992a;191-197.
45. Gordon D.L., Sadlon T., et al. Expression of Cd59, a regulator of the membrane attack complex of complement, on human astrocytes. Molecular Brain Research. 18:1993;335-338.
46. Gordon D.L., Sadlon T.A., et al. Human astrocytes express membrane cofactor protein (Cd46), a regulator of complement activation. Journal of Neuroimmunology. 36:1992b;199-208.
47. Heese K., Hock C., et al. Inflammatory signals induce neurotrophin expression in human microglial cells. Journal of Neurochemistry. 70:1998;699-707.
48. Huang J., Kim L.J., et al. Neuronal protection in stroke by an sLe(x)-glycosylated complement inhibitory protein. Science. 285:1999;595-599.
49. Ischenko A., Sayah S., et al. Expression of a functional anaphylatoxin C3a receptor by astrocytes. Journal of Neurochemistry. 71:1998;2487-2496.
50. Itagaki S., Akiyama H., et al. Ultrastructural-localization of complement membrane attack complex (Mac)-like immuno-reactivity in brains of patients with Alzheimers-disease. Brain Research. 645:1994;78-84.
51. Jiang H.X., Burdick D., et al. Beta-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A-chain. Journal of Immunology. 152:1994;5050-5059.
52. Johnson S.A., Lampertetchells M., et al. Complement messenger-RNA In the mammalian brain-responses to Alzheimers-disease and experimental brain lesioning. Neurobiology of Aging. 13:1992;641-648.
53. Korb L.C., Ahearn J.M. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complemement deficiency and systemic lupus erythematous revisited. Journal of Immunology. 158:1997;4525-4528.
54. Lacy M., Jones J., et al. Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia. Journal of Neuroimmunology. 61:1995;71-78.
55. Lampertetchells M., Pasinetti G.M., et al. Regional localisation of cells containing complement C1q and C4 mRNAs in the frontal cortex during Alzheimer's disease. Neurodegeneration. 2:1993;111-121.
56. Levistrauss M., Mallat M. Primary cultures of murine astrocytes produce C-3 and factor-B, 2 components of the alternative pathway of complement activation. Journal of Immunology. 139:1987;2361-2366.
57. Mason J.C., Yarwood H., et al. Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood. 94:1999;1673-1682.
58. May P.C., Johnson S.A., et al. Altered gene-expression in Alzheimers-disease brain-tissue. Canadian Journal of Neurological Sciences. 16:1989;473-476.
59. May P.C., Lampertetchells M., et al. Dynamics of gene-expression for a hippocampal glycoprotein elevated in Alzheimers-disease and in response to experimental lesions in rat. Neuron. 5:1990;831-839.
60. McGeer P.L., Akiyama H., et al. Activation of the classical complement pathway in brain-tissue of Alzheimer patients. Neuroscience Letters. 107:1989;341-346.
61. McGeer P.L., Kawamata T., et al. Distribution of clusterin in Alzheimer brain-tissue. Brain Research. 579:1992;337-341.
62. McGeer P.L., Walker D.G., et al. Detection of the membrane inhibitor of reactive lysis (Cd59) in diseased neurons of Alzheimer brain. Brain Research. 544:1991;315-319.
63. McGeer P.L., Walker D.G., et al. Complement proteins, activators and inhibitors in Alzheimer-disease brain. Abstracts of Papers of the American Chemical Society. 210:1995;247. MEDI.
64. Morgan B.P. Complement membrane attack on nucleated cells - resistance, recovery and non-lethal effects. Biochemical Journal. 264:1989;1-14.
65. Morgan B.P. Effects of the membrane attack complex of complement on nucleated cells. Current Topics in Microbiology and Immunology. 178:1992;115-140.
66. Morgan B.P., Gasque P. Expression of complement in the brain: role in health and disease. Immunology Today. 17:1996;461-466.
67. Morgan B.P., Gasque P. Extrahepatic complement biosynthesis: where, when and why? Clinical and Experimental Immunology. 107:1997;1-7.
68. Morgan B.P., Gasque P., et al. The role of complement in disorders of the nervous system. Immunopharmacology. 38:1997;43-50.
69. Morgan B.P., Harris C.L. Regulation in the complement system. Morgan B.P., Harris B.P. Complement Regulatory Proteins. 1999;32-40 Academic Press, San Diego.
70. Morgan B.P., Meri S. Membrane-proteins that protect against complement lysis. Springer Seminars in Immunopathology. 15:1994;369-396.
71. Morgan D.G., Johnson S.A., et al. Differences in gene-expression in the cerebral-cortex of Alzheimers-disease and age-matched control brains. Journal of Cellular. 196:1987.
72. Niculescu F., Rus H., et al. Activation of ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent. Journal of Immunology. 158:1997;4405-4412.
73. Niculescu F.I., Rus H.G., et al. Terminal complement Complexes (TCC) activate GTP-binding regulatory proteins. Faseb Journal. 8:1994;A1432.
74. Piddlesden S.J., Jiang S.S., et al. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. Journal of Neuroimmunology. 71:1996;173-177.
75. Piddlesden S.J., Morgan B.P. Killing of rat glial-cells by complement-deficiency of the rat analog of CD59 is the cause of oligodendrocyte susceptibility to lysis. Journal of Neuroimmunology. 48:1993;169-176.
76. Poirier J., May P., et al. Astroglial gene-expression in response to hippocampal deafferentation in the rat and in Alzheimer's-disease. Neurobiology of Aging. 11:1990;328.
77. Pouplardbarthelaix A., Dubas F., et al. An immunohistological study of the brain-lesions in Alzheimer-disease and senile dementia of Alzheimers type-evidence of complement components in vascular and senile plaque amyloid. Neuropathology and Applied Neurobiology. 12:1986;609-610.
78. Rogers J. Inflammation and Alzheimers-disease-therapeutic implications. CNS Drugs. 1:1994;241-244.
79. Rogers J., Cooper N.R., et al. Complement activation by beta-amyloid in Alzheimer-disease. Proceedings of the National Academy of Sciences of the United States of America. 89:1992;10016-10020.
80. Rus H., Soane L., et al. Oligodendrocyte protection by sublytic C5b-9 from apoptotic cell death. Molecular Immunology. 35:1998;278.
81. Sayah S., Ischenko A.M., et al. Expression of cytokines by human astrocytomas following stimulation by C3a and C5a anaphylatoxins: specific increase in interleukin-6 mRNA expression. Journal of Neurochemistry. 72:1999;2426-2436.
82. Sayah S., Leon P., et al. C3a and C5a anaphylatoxins receptors. MS-Medicine Sciences. 14:1998;291-299.
83. Schenk D., Barbour R., et al. Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
84. Scolding N.J., Morgan B.P., et al. The expression of complement regulatory proteins by adult human oligodendrocytes. Journal of Neuroimmunology. 84:1998;69-75.
85. Scolding N.J., Morgan B.P., et al. Normal rat serum cytotoxicity against syngeneic oligodendrocytes-complement activation and attack in the absence of anti-myelin antibodies. Journal of the Neurological Sciences. 89:1989;289-300.
86. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 399:1999;A23-A31.
87. Shen Y., Li R., et al. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Research. 769:1997;391-395.
88. Shirazi Y., McMorris F.A., et al. The role of terminal complement complexes in arachidonic-acid release from rat oligodendrocyte-X-C6 glioma cell hybrids. Journal of Neuroimmunology. 16:1987;160.
89. Shirazi Y., McMorris F.A., et al. Arachidonic-acid mobilization and phosphoinositide turnover by the terminal complement complex, C5b-9, in rat oligodendrocyte X C-6 glioma cell hybrids. Journal of Immunology. 142:1989;4385-4391.
90. Singhrao S.K., Neal J.W., et al. Role of complement in the aetiology of Pick's disease? Journal of Neuropathology and Experimental Neurology. 55:1996;578-593.
91. Singhrao S.K., Neal J.W., et al. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Experimental Neurology. 159:1999a;362-376.
92. Singhrao S.K., Neal J.W., et al. Differential expression of individual complement regulators in the brain and choroid plexus. Laboratory Investigation. 79:1999b;1247-1259.
93. Spiller O.B., Moretto G., et al. Complement expression on astrocytes and astrocytoma cell lines: failure of complement regulation at the C3 level correlates with very low CD55 expression. Journal of Neuroimmunology. 71:1996;97-106.
94. Stahel P.P., Frei K., et al. Evidence for intrathecal synthesis of alternative pathway complement activation proteins in experimental meningitis. American Journal of Pathology. 151:1997a;897-904.
95. Stahel P.P., Nadal D., et al. Complement C3 and factor B cerebrospinal fluid concentrations in bacterial and aseptic meningitis. Lancet. 349:1997b;1886-1887.
96. Tacnet P., Galvan M., et al. In vitro analysis of C1 activation by A beta Alzheimer's disease-related peptides. Molecular Immunology. 36:1999;89.
97. Tedesco F., Pausa M., et al. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. Journal of Experimental Medicine. 185:1997;1619-1627.
98. Tenner A.J. Membrane receptors for soluble defense collagens. Current Opinion in Immunology. 11:1999;34-41.
99. Terai K., Walker D.G., et al. Neurons express proteins of the classical complement pathway in Alzheimer disease. Brain Research. 769:1997;385-390.
100. Turner M.W. Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunology today. 17:1996;532-540.
101. Valazquez P., Cribbs D.H., et al. Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. Nature Medicine. 3:1997;77-79.
102. Vanguri P., Koski C.L., et al. Complement activation by isolated myelin-activation of the classical pathway in the absence of myelin-specific antibodies. Proceedings of the National Academy of Sciences of the United States of America - Biological Sciences. 79:1982;3290-3294.
103. Vanguri P., Shin M.L. Activation of complement by myelin-identification of C1-binding proteins of human myelin from central nervous-tissue. Journal of Neurochemistry. 46:1986;1535-1541.
104. Vedeler C., Ulvestad E., et al. The expression of CD59 in normal human nervous-tissue. Immunology. 82:1994;542-547.
105. Veerhuis R., Janssen I., et al. Alzheimer amyloid plaque associated cytokines increase C1r and C1s, not C1-inhibitor, expression by human astrocytes and neuroblastoma cell lines in vitro. Molecular Immunology. 35:1998a;312.
106. Veerhuis R., Janssen I., et al. Complement C1-inhibitor expression in Alzheimer's disease. Acta Neuropathologica. 96:1998b;287-296.
107. Veerhuis R., Vandervalk P., et al. Complement activation in amyloid plaques in Alzheimers-disease brains does not proceed further than C3. Virchows Archiv - An International Journal of Pathology. 426:1995;603-610.
108. Vonsattel J.P.G., DiFiglia M. Huntington disease. Journal of Neuropathology and Experimental Neurology. 57:1998;369-384.
109. Walker D.G., Kim S.U., et al. Complement and cytokine gene-expression in cultured microglia derived from post-mortem human brains. Journal of Neuroscience Research. 40:1995a;478-493.
110. Walker D.G., Kim S.U., et al. Expression of complement C4 and C9 genes by human astrocytes. Brain Research. 809:1998;31-38.
111. Walker D.G., McGeer P.L. Complement gene-expression in human brain-comparison between normal and Alzheimer-disease cases. Molecular Brain Research. 14:1992;109-116.
112. Walker D.G., McGeer P.L., et al. Complement gene-expression in neuroblastoma and astrocytoma cell-lines of human-origin. Neuroscience Letters. 157:1993;99-102.
113. Walker D.G., McGeer P.L. Vitronectin expression in Purkinje cells in the human cerebellum. Neuroscience Letters. 251:1998;109-112.
114. Walker D.G., Yasuhara O., et al. Complement C1 inhibitor is produced by brain-tissue and is cleaved in Alzheimer-disease. Brain Research. 675:1995b;75-82.
115. Webster S., Bradt B., et al. Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide. Journal of Neurochemistry. 69:1997a;388-398.
116. Webster S., Lue L.F., et al. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiology of Aging. 18:1997b;415-421.
117. Witte D.P., Welch T.R., et al. Detection and cellular-localization of human C4 gene-expression in the renal tubular epithelial-cells and other extrahepatic epithelial sources. American Journal of Pathology. 139:1991;717-724.
118. Yang C., Barnum S.R. Expression and regulation of decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 in the human astroglioma cell-line, D54-MG, and primary rat astrocytes. Journal of Immunology. 150:1993;A227.
119. Yang C.Y., Jones J., et al. Production and regulation of decay-accelerating factor by the astroglioma cell-line D54-Mg. Faseb Journal. 6:1992;A1452.
120. Yang C.Y., Jones J.L., et al. Expression of decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 in the human astroglioma cell-line, D54-MG, and primary rat astrocytes. Journal of Neuroimmunology. 47:1993;123-132.
121. Yasojima K., McGeer E.G., et al. Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease. Brain Research. 833:1999a;297-301.
122. Yasojima K., Schwab C., et al. Up-regulated production and activation of the complement system in Alzheimer's disease brain. American Journal of Pathology. 154:1999b;927-936.
123. Yasuhara O., Aimi Y., et al. Expression of the complement membrane attack complex and its inhibitors in Pick disease brain. Brain Research. 652:1994;346-349.
124. Zajicek J., Wing M., et al. Human oligodendrocytes are not sensitive to complement-a study of Cd59 expression in the human central-nervous-system. Laboratory Investigation. 73:1995;128-138.
125. Zhan S.S., Veerhuis R., et al. Immunohistochemical distribution of the inhibitors of the terminal complement complex in Alzheimers-disease. Neurodegeneration. 3:1994;111-117.